Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ARTL - Artelo Biosciences Inc


IEX Last Trade
1.27
-0.040   -3.150%

Share volume: 3,601
Last Updated: Fri 30 Aug 2024 07:38:15 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$1.31
-0.04
-3.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
16%
Profitability 15%
Dept financing 10%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
1.56%
1 Month
-4.41%
3 Months
-1.52%
6 Months
-16.13%
1 Year
-30.11%
2 Year
-65.88%
Key data
Stock price
$1.27
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.15 - $2.98
52 WEEK CHANGE
-$0.30
MARKET CAP 
4.196 M
YIELD 
N/A
SHARES OUTSTANDING 
3.228 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.53
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$8,603
AVERAGE 30 VOLUME 
$7,723
Company detail
CEO:
Region: US
Website:
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.

Recent news